or
Remember me
Back
Listed biotech company Mesoblast says it is seeing positive signs for the use of its stem cell therapy in treating critically ill COVID-19 patients.
The company said 83 per cent of ventilator-dependent patients with a high risk of mortality who received its stem cell treatment have survived during early compassionate usage in New York's Mount Sinai hospital.
A daily snapshot of everything from market open to close.